ImmuCell Corporation - Asset Resilience Ratio

Latest as of December 2024: 0.11%

ImmuCell Corporation (ICCC) has an Asset Resilience Ratio of 0.11% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ImmuCell Corporation current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$50.40K
Cash + Short-term Investments

Total Assets

$45.10 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2021)

This chart shows how ImmuCell Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ImmuCell Corporation (ICCC) total assets.

Liquid Assets Composition Over Time

This chart breaks down ImmuCell Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ImmuCell Corporation long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $50.40K 0.11%
Total Liquid Assets $50.40K 0.11%

Asset Resilience Insights

  • Limited Liquidity: ImmuCell Corporation maintains only 0.11% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

ImmuCell Corporation Industry Peers by Asset Resilience Ratio

Compare ImmuCell Corporation's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for ImmuCell Corporation (2002–2021)

The table below shows the annual Asset Resilience Ratio data for ImmuCell Corporation.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2021-12-31 0.00% $-468.00 $44.47 Million -2.47pp
2020-12-31 2.47% $996.50K $40.35 Million -3.94pp
2019-12-31 6.41% $2.48 Million $38.69 Million --
2017-12-31 0.00% $0.00 $34.30 Million --
2016-12-31 22.16% $5.47 Million $24.70 Million -8.41pp
2015-12-31 30.57% $4.46 Million $14.60 Million +8.05pp
2014-12-31 22.52% $2.49 Million $11.05 Million -4.71pp
2013-12-31 27.23% $2.98 Million $10.96 Million +6.93pp
2012-12-31 20.31% $2.24 Million $11.03 Million -17.70pp
2011-12-31 38.01% $4.18 Million $10.99 Million +8.00pp
2010-12-31 30.02% $3.23 Million $10.75 Million -6.14pp
2009-12-31 36.16% $3.61 Million $9.98 Million -1.90pp
2008-12-31 38.05% $3.85 Million $10.13 Million -2.46pp
2007-12-31 40.52% $4.22 Million $10.41 Million -5.82pp
2006-12-31 46.33% $5.27 Million $11.36 Million +6.66pp
2005-12-31 39.68% $3.95 Million $9.96 Million +10.82pp
2004-12-31 28.85% $2.75 Million $9.53 Million +18.00pp
2003-12-31 10.85% $888.32K $8.19 Million +0.38pp
2002-12-31 10.48% $787.05K $7.51 Million --
pp = percentage points

About ImmuCell Corporation

NASDAQ:ICCC USA Biotechnology
Market Cap
$90.64 Million
Market Cap Rank
#19666 Global
#4494 in USA
Share Price
$9.98
Change (1 day)
+3.85%
52-Week Range
$4.56 - $11.72
All Time High
$11.88
About

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more